AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|
24.9 C
New York
Tuesday, July 28, 2026

Tag: medical needs

newssourceFORcompanyinformationcontent1releasesmarket

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas 
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Haemonetics Updates Financial Reporting Segments

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedical needs

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers